FINP
FINAL DECISION TRANSACTION PROCESSED BY IB
20/03/2023
Voltar para busca
Dado oficial do USPTO
PHARMTRACE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PHARMTRACE
ST13
US500000079069710Classe
35, 41, 42, 44
Pedido
79069710
Registro
3799744
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
53
Atualização mais recente
20/03/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 41, 42, 44
Data de depósito
11/02/2009
Data de registro
08/06/2010
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/09/2020
Última transação
01/09/2020
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
Berlin, DE
Examinador
BIBB, SCOTT
Unidade examinadora
L90
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
Pharmtrace klinische Entwicklung GmbH
Representantes
Andrew R. Silverman MacElree Harvey, Ltd.
Classificação técnica
Classes Nice
Classe 35Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Advertising and advertisement services; marketing services regarding clinical trialsbusiness consulting services with respect to marketing clinical trials; providing advertisingmarketing and promotional services for the pharmaceutical and medical products of othersmarketing services regarding pharmaceutical products by means of promoting clinical trial dataincluding diagnostic imaging procedures; business management; business administration; providing office functions
Classe 41
Education servicesproviding classesseminarsworkshops and training in the fields of drug developmentlife cycle managementclinical research and developmentdiagnostic imaging and molecular medicine; provision of trainingsubject-specific further training in the field of clinical research and developmentdiagnostic imaging and molecular medicine; organization and arranging of seminars; entertainmentorganization of exhibitions for cultural or educational purposes and organizing community sporting and cultural events
Classe 42
Scientific and technological services and research and design relating theretoscientific research and developmentproviding medical and scientific research information in the fields of pharmaceuticalsclinical trialsdrug developmentlife cycle managementclinical research and developmentdiagnostic imaging and molecular medicine; industrial analysis and research services in the fields of pharmaceuticalsclinical trialsdrug developmentlife cycle managementclinical research and developmentdiagnostic imaging and molecular medicine; design and development of computer hardware and software
Classe 44
Medical and veterinary services; hygienic and beauty care for human beings and animals; advisory services relating to pharmaceutical preparations
Publicações
Histórico de despachos e eventos da marca no USPTO.
53 publicações encontradas
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
09/12/2022
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
07/12/2022
XXCR
GENERIC MADRID TRANSACTION CREATED
07/12/2022
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
01/05/2021
FINT
FINAL DECISION TRANSACTION PROCESSED BY IB
23/01/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/12/2020
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
01/09/2020
71AG
REGISTERED-SEC.71 ACCEPTED
01/09/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/09/2020
ES71
TEAS SECTION 71 RECEIVED
04/06/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/05/2020
RNWL
INTERNATIONAL REGISTRATION RENEWED
23/08/2019
RFNT
REFUSAL PROCESSED BY IB
18/07/2019
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
08/06/2019
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
28/12/2017
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
28/09/2017
INPC
INVALIDATION PROCESSED
28/09/2017
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
27/09/2017
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
28/01/2017
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
27/01/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
19/01/2017
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
10/01/2017
PR71
POST REGISTRATION ACTION MAILED - SEC.71
13/07/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/07/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/06/2016
ES71
TEAS SECTION 71 RECEIVED
03/06/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/02/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/09/2010
FIMP
FINAL DISPOSITION PROCESSED
09/09/2010
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/09/2010
R.PR
REGISTERED-PRINCIPAL REGISTER
08/06/2010
PUBO
PUBLISHED FOR OPPOSITION
23/03/2010
NPUB
NOTICE OF PUBLICATION
03/03/2010
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
17/02/2010
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/02/2010
ACEC
AMENDMENT FROM APPLICANT ENTERED
20/01/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/01/2010
ALIE
ASSIGNED TO LIE
20/01/2010
PAPER RECEIVED
12/01/2010
RFNT
REFUSAL PROCESSED BY IB
19/09/2009
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/07/2009
RFRR
REFUSAL PROCESSED BY MPU
15/07/2009
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
15/07/2009
CNRT
NON-FINAL ACTION WRITTEN
14/07/2009
MAFR
APPLICATION FILING RECEIPT MAILED
14/07/2009
DOCK
ASSIGNED TO EXAMINER
10/07/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/07/2009
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/07/2009
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PHARMTRACE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.